What is PML and how does Tysabri (natalizumab) affect the risk?
PML (progressive multifocal leukoencephalopathy) is a rare, serious brain infection caused by the JC virus. With Tysabri (natalizumab), the risk of PML rises because the drug suppresses certain immune responses, which can allow the JC virus to reactivate and infect the brain.
In clinical use, the main driver of risk is prior exposure to the JC virus, plus other factors such as how long someone has been on Tysabri and whether they have used certain other immunosuppressive drugs.
What makes someone more likely to get PML on Tysabri?
Clinicians generally estimate PML risk based on a combination of factors, including:
- JC virus antibody status (JC virus positivity increases risk)
- Duration of Tysabri treatment (risk increases the longer treatment continues)
- Prior immunosuppressant use (raises risk further in some patients)
- Whether someone has been on Tysabri before (residual risk depends on overall treatment history)
These factors are used to support individualized risk discussions and decisions about continuing, stopping, or switching therapy.
How high is the PML risk, and does it change over time?
Yes. PML risk with Tysabri is not flat; it increases with longer exposure. That is why risk-benefit planning often becomes more careful as treatment duration grows, especially for people who are JC virus–positive and/or have additional risk factors.
What should patients watch for if they’re worried about PML?
PML symptoms can develop over days to weeks and may include new or worsening neurologic problems, such as:
- Weakness or clumsiness on one side of the body
- Vision changes
- Trouble speaking or coordinating movements
- Memory or personality changes
Because these symptoms can overlap with other neurologic conditions, any new persistent neurologic symptoms while on Tysabri should trigger urgent medical evaluation.
What happens if PML is suspected while on Tysabri?
If PML is suspected, Tysabri is typically stopped immediately and clinicians evaluate the patient urgently (often with brain imaging and JC virus testing). Management then focuses on confirming the diagnosis and addressing immune recovery while controlling symptoms.
Are there ways to reduce the risk of PML on Tysabri?
Common risk-reduction approaches include:
- Using JC virus antibody testing and regular monitoring to reassess risk over time
- Applying individualized risk stratification tied to treatment duration
- Considering alternative dosing strategies or switching therapies when risk becomes unacceptable for a given patient profile (decided by the treating neurologist)
If you share your JC virus antibody status and how long you’ve been on Tysabri (and whether you’ve used prior immunosuppressants), I can help you interpret what factors usually push PML risk higher or lower.
Source
- DrugPatentWatch.com – Tysabri (natalizumab) PML information